Literature DB >> 20428681

Rhodococcus equi isolation from sputum of patients with suspected tuberculosis.

Paulo da Silva1, Marcelo Miyata, Daisy Nakamura Sato, Adolfo Carlos Barreto Santos, Natália Helena Mendes, Clarice Queico Fujimura Leite.   

Abstract

Rhodococcus equi has emerged as an opportunistic pathogen associated with pulmonary, invasive or systemic infections in immunocompromised patients. We report the identification of 51 R. equi isolates found in sputum samples of 546 individuals suspected to have pulmonary tuberculosis in two Public Health Hospital Units in Brazil. The epidemiology of R. equi infection as well as the phenotypic identification and drug susceptibility profile of isolates are described in this paper.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428681     DOI: 10.1590/s0074-02762010000200015

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  3 in total

1.  In-vitro antimicrobial activity and identification of bioactive components using GC-MS of commercially available essential oils in Saudi Arabia.

Authors:  Syed Amir Ashraf; Eyad Al-Shammari; Talib Hussain; Shaikh Tajuddin; Bibhu Prasad Panda
Journal:  J Food Sci Technol       Date:  2017-09-21       Impact factor: 2.701

2.  Short report: Identification of virulence-associated plasmids in Rhodococcus equi in humans with and without acquired immunodeficiency syndrome in Brazil.

Authors:  Márcio Garcia Ribeiro; Shinji Takai; Agueda Castagna de Vargas; Ana Luiza Mattos-Guaraldi; Thereza Cristina Ferreira Camello; Ryoko Ohno; Hajime Okano; Aristeu Vieira da Silva
Journal:  Am J Trop Med Hyg       Date:  2011-09       Impact factor: 2.345

3.  In vitro performances of novel co-spray-dried azithromycin/rifampicin microparticles for Rhodococcus equi disease treatment.

Authors:  Elisa Rampacci; Maria Luisa Marenzoni; Elisabetta Chiaradia; Fabrizio Passamonti; Maurizio Ricci; Marco Pepe; Mauro Coletti; Stefano Giovagnoli
Journal:  Sci Rep       Date:  2018-08-14       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.